Obesity is a growing global health issue that leads to numerous complications such as type 2 diabetes, heart disease, and high blood pressure. Lifestyle changes like diet and exercise have long been the cornerstone of weight management, but they often struggle to provide long-term results. A new study on semaglutide, a once-weekly injectable medication, has shown promising results in helping adults with obesity achieve significant, sustainable weight loss. Here, we explore the findings from the STEP 1 trial, which examined the effects of semaglutide when used alongside lifestyle interventions.

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is commonly used to treat type 2 diabetes. In higher doses, it has shown potential as an effective weight loss treatment for adults with obesity or those who are overweight and have weight-related conditions, such as hypertension or sleep apnea.

Study Overview

The STEP 1 trial was a 68-week randomized, double-blind, placebo-controlled study conducted at 129 sites across 16 countries. It involved 1,961 participants, all aged 18 or older, who were either obese (with a body mass index (BMI) of 30 or greater) or overweight with related conditions (BMI ≥ 27). Importantly, the participants did not have diabetes. The goal of the study was to determine whether semaglutide could help participants lose weight in combination with a lifestyle intervention (diet and exercise).

Participants were divided into two groups: one received semaglutide 2.4 mg weekly, while the other received a placebo, both alongside lifestyle counseling.

Major Findings from the Study

Significant Weight Loss
‍

The study found that semaglutide injection for weight loss was highly effective at promoting weight loss. The group receiving semaglutide saw an average 14.9% reduction in body weight by week 68, compared to just 2.4% in the placebo group. This is a substantial difference, highlighting the potential of semaglutide to aid in weight management for individuals struggling with obesity.

- 86.4% of participants in the semaglutide group lost at least 5% of their body weight

- 69.1% lost at least 10%

- 50.5% lost at least 15%

- About 32% of participants achieved weight loss of 20% or more

This weight loss is comparable to what might be expected after bariatric surgery, with semaglutide offering a less invasive alternative.

Improvements in Health Markers

In addition to weight loss, semaglutide also led to notable improvements in various cardiometabolic risk factors, which are important indicators of overall health. Participants who received semaglutide experienced:

- Reduction in waist circumference (average of 13.5 cm)

- Decreased blood pressure

- Improved lipid levels (cholesterol and triglycerides)

- Better blood sugar control, especially in those with prediabetes

These improvements suggest that semaglutide could have broader health benefits, including reducing the risk of cardiovascular disease and diabetes, which are common complications associated with obesity.

Side Effects and Safety

While semaglutide proved to be effective in promoting weight loss and improving health markers, it was not without side effects. The most commonly reported side effects included gastrointestinal issues such as nausea, diarrhea, and vomiting. However, these side effects were generally mild to moderate and temporary in nature.

More participants in the semaglutide group discontinued treatment due to these adverse effects compared to the placebo group. However, the severity of the side effects did not lead to significant safety concerns during the trial.

How Semaglutide Works

Semaglutide works by mimicking a natural hormone in the body called GLP-1, which helps regulate appetite and glucose metabolism. By increasing GLP-1 activity, semaglutide reduces hunger and enhances feelings of fullness. As a result, participants tend to eat less, leading to weight loss.

The weekly dosage is administered through a subcutaneous injection, which makes it a convenient treatment option compared to daily medications or surgeries like gastric bypass.

Conclusion: A New Hope for Weight Loss

The STEP 1 trial demonstrated that semaglutide, when combined with lifestyle interventions, can lead to substantial, sustainable weight loss in adults with obesity or overweight. Not only does it help individuals lose weight, but it also improves crucial health markers, offering hope for those struggling with obesity-related health issues.

While the treatment does have some side effects, such as gastrointestinal discomfort, these are generally manageable and transient. With continued research and ongoing trials, semaglutide may offer a long-term solution to the global obesity epidemic.

If you are considering weight loss treatments, it’s essential to speak with your healthcare provider to determine if semaglutide could be a suitable option for your weight management journey.

‍